Replimune, uniQure rise; FDA commissioner Makary plans to resign

Moderna

12/05/2026 18:24

** Shares of biotech firm Replimune Group REPL.O rise 14.7% to $4.2

** U.S. Food and Drug Administration Commissioner Marty Makary plans to resign on Tuesday, according to two sources familiar with the situation

** FDA Deputy Commissioner Kyle Diamantas will lead the agency in an acting capacity, Politico, which first reported the development, says

** Last month, the health regulator declined to approve REPL's drug for the second time

** U.S.-listed shares of Dutch gene therapy developer uniQure UQ1.F rise 6.1% to $29.4

** FDA in March had called for a new study to support the approval of uniQure's gene therapy for the rare, inherited neurodegenerative disorder, and rejected its most recent trial for not including participants given a placebo

** Shares of vaccine makers including Pfizer PFE.N and Moderna MRNA.O were up over 1%

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))